Image de couverture de livre

Mac‐2 Binding Protein Glycosylation Isomer as a Dynamic Biomarker in Obstructive Cholestasis

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Takanobu Iwadare, Takefumi Kimura
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Hepatology Research
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Mac‐2 Binding Protein Glycosylation Isomer (M2BPGi) Increases in Patients With Obstructive Jaundice through the Activation of Hepatic Stellate Cells by Bile Acids
par: Norihiro Ishii, et autres
Publié: (2025)

Metabolic Effect on Serum Mac‐2 Binding Protein Glycan Isomer Level and Its Normal Range in the Health Checkup Examinee
par: Wataru Yoshioka, et autres
Publié: (2025)

Lipolysis‐Stimulated Lipoprotein Receptor Gene Variants as a Cause of Progressive Familial Intrahepatic Cholestasis: A Case Report
par: Yugo Takaki, et autres
Publié: (2025)

Expression patterns of hepatic Mac2‐BP in the liver microenvironment
par: Tomoko Tadokoro
Publié: (2025)

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin
par: Akiyo Ishiguro, et autres
Publié: (2026)

Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
par: Nobuharu Tamaki, et autres
Publié: (2024)

Hepatic Mac2‐BP expression depends on liver fibrosis and inflammation due to fat accumulation in patients with metabolic dysfunction‐associated steatotic liver disease
par: Haruki Uojima, et autres
Publié: (2024)

Lymphocyte‐to‐Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma
par: Satoshi Tanaka
Publié: (2025)

Oncogenic Signaling Activation and Potential Biomarkers in Congestive Hepatopathy Revealed by Proteomic Analysis
par: Yoshihito Morimoto, et autres
Publié: (2026)

Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug‐Induced Liver Injury
par: Kosuke Saito, et autres
Publié: (2025)

Letter to ‘‘Circulating Myostatin Levels as a Prognostic Biomarker in Patients With Acute Liver Failure and Late‐Onset Hepatic Failure’’
par: Yanyan Zhang, et autres
Publié: (2025)

Enhancing Robustness in Prognostic Biomarker Research: A Letter on Validating Model Assumptions and Handling Zero Events
par: Haiying Hu, et autres
Publié: (2025)

Comment on“Anti‐MRPS27 Antibody: A Novel Diagnostic Biomarker for Autoimmune Hepatitis Identified via a Human Proteome Microarray”
par: Wei Ouyang, et autres
Publié: (2026)

Investigation of Possible Telomerase Reverse Transcriptase Promoter Mutation in Human Chemically Induced Liver Progenitors
par: Baglan Askeyev, et autres
Publié: (2025)

Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
par: Yuta Myojin, et autres
Publié: (2025)

Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection
par: Hiroji Shinkawa, et autres
Publié: (2025)

Comment on “Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection”
par: Minghai Shen, et autres
Publié: (2025)

High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma
par: Xuefeng Li, et autres
Publié: (2024)

Dynamic Early Survival Prediction Model for Hepatocellular Carcinoma Patients Treated With Atezolizumab and Bevacizumab: A Longitudinal Deep Learning Analysis
par: Weiming Li, et autres
Publié: (2025)

Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
par: Takanori Suzuki, et autres
Publié: (2025)

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis
par: Ryo Sato, et autres
Publié: (2025)

Development of Simplified Risk Assessment Scoring System for Sarcopenia in Patients With Chronic Liver Disease
par: Atsushi Hiraoka, et autres
Publié: (2025)

FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan‐Asian Study
par: Yuta Maruki, et autres
Publié: (2025)

Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study
par: Masayuki Ueno, et autres
Publié: (2025)

Successful Retreatment of Glecaprevir‐Pibrentasvir for Hepatitis C Virus Genotype 2a Infection in Patient Whose Cirrhosis Improved From Decompensation to Compensation After Sofosbuvir–Velpatasvir Therapy
par: Tatsuo Kanda, et autres
Publié: (2025)

The change in Fibrosis‐4 index in Japanese patients with type 2 diabetes treated by a fixed‐ratio combination therapy of insulin degludec and liraglutide: A retrospective observational study
par: Hiroyuki Ito, et autres
Publié: (2024)

Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis
par: Takao Miwa, et autres
Publié: (2025)

Fibroblast growth factor receptor 2 alterations in intrahepatic cholangiocarcinoma: Prevalence and clinical implications in Asian populations
par: Kyoko Oura, et autres
Publié: (2025)

ALDH2 Polymorphism in Alcohol‐Related Cirrhosis Requiring Liver Transplantation: A Recipient–Donor Analysis
par: Noriyo Yamashiki, et autres
Publié: (2026)

Optimizing VCTE and ELF Thresholds for Treatment‐Eligible F2–F3 Fibrosis in Japanese Patients With MASLD
par: Yuya Seko, et autres
Publié: (2026)

Limited use of FIB‐4 index in patients under 65 years of age with type 2 diabetes mellitus
par: Mimi Kim, et autres
Publié: (2024)

Multicenter observational study to characterize fibroblast growth factor receptor 2 fusions or rearrangements in patients with advanced/metastatic cholangiocarcinoma
par: Tomoyuki Satake, et autres
Publié: (2025)

Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey
par: Yuki Kugiyama, et autres
Publié: (2025)

Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study
par: Ayaka Tanifuji, et autres
Publié: (2024)

Do Patients With Alcoholic Cirrhosis Accurately Recognize Their Alcohol Tolerance? A Study Comparing Self‐Perception and ALDH2/ADH1B Genotype
par: Tomoko Tadokoro, et autres
Publié: (2025)

Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects
par: Ting Wang, et autres
Publié: (2024)

CXCL6 Is a Novel Biliary Marker and a Downstream Target of MMP7 in Biliary Atresia
par: Fanyang Kong, et autres
Publié: (2025)

Natural killer group 2D‐major histocompatibility complex class I polypeptide‐related sequence A activation enhances natural killer cell‐mediated immunity against hepatocellular carcinoma: A review
par: Jun Arai, et autres
Publié: (2024)

Progressive Sarcopenia as a Prognostic Marker in the Era of Immunotherapy
par: Takeshi Okamoto, et autres
Publié: (2025)

Is Glucose Intolerance a Precursor of Cachexia in Patients With Liver Cirrhosis?
par: Tsutomu Nishida, et autres
Publié: (2025)